Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anaplastic Large Cell Lymphoma, ALK-Positive: early-phase trial registry
1 of 5 indexed Anaplastic Large Cell Lymphoma, ALK-Positive trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Anaplastic Large Cell Lymphoma, ALK-Positive: 5 US clinical trials tracked, 1 recruiting.
Anaplastic Large Cell Lymphoma, ALK-Positive is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is New York Medical College, running 1 of these trials.
Enrollment posture brief
Registry condition anaplastic-large-cell-lymphoma-alk-positive
OPEN 1 | RECR 20% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Anaplastic Large Cell Lymphoma, ALK-Positive lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anaplastic Large Cell Lymphoma, ALK-Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anaplastic Large Cell Lymphoma, ALK-Positive is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anaplastic Large Cell Lymphoma, ALK-Positive research.
New York Medical College accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Anaplastic Large Cell Lymphoma, ALK-Positive trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Anaplastic Large Cell Lymphoma, ALK-Positive research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT06176690
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
NCT02978625
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
NCT03113500
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
New York Medical College
NCT07013565
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
NCT02561273
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Anaplastic Large Cell Lymphoma, ALK-Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anaplastic Large Cell Lymphoma, ALK-Positive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anaplastic Large Cell Lymphoma, ALK-Positive page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Anaplastic Large Cell Lymphoma, ALK-Positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- New York Medical College sponsors the most Anaplastic Large Cell Lymphoma, ALK-Positive trials on record, review their full trial history before evaluating a specific study. See New York Medical College's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Large Cell Lymphoma, ALK-Positive condition card totals 5 registered trials; most-linked intervention Etoposide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.